MedPath

Combination of Hydroquinone and Fractional CO2 Laser vs. Hydroquinone Monotherapy in Melasma Treatment: A Randomized Split-face Clinical Trial

Phase 3
Conditions
melasma.
Chloasma
Registration Number
IRCT20171222037987N1
Lead Sponsor
Esfahan University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
Female
Target Recruitment
40
Inclusion Criteria

Female patients
Age range of 20-50 years
Fitzpatrick skin types II-V
Bilateral melasma on cheeks

Exclusion Criteria

History of receiving laser therapy and topical therapeutic agents in the previous three months
History of receiving Isotretinoin in the past six months
History of receiving OCP, other bleaching creams, phenytoin, phototoxic and photoallergic drugs
Pregnancy
Lactating

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Severity of the melasma lesions was assessed objectively based on Darkness (D) and Homogeneity (H) using a 7-point scale (0-6). Timepoint: The darkness and homogeneity scores were obtained in the first visit and the 3 laser sessions at three-week intervals and the follow-up sessions at 1 and 3 months after the last laser session. Method of measurement: darkness and homogeneity : 7-point scale(compare with the sample) patient's satisfaction with the treatment :visual analogue scale (VAS) by scoring between 0 and 10 response to treatment : physician global assessment.
Secondary Outcome Measures
NameTimeMethod
Patient's satisfaction with the treatment. Timepoint: 3 months after the last laser session. Method of measurement: visual analogue scale (VAS) by scoring between 0 and 10.
© Copyright 2025. All Rights Reserved by MedPath